ライフサイエンスコーパス: vasodilator

1 rsisted despite administration of a coronary vasodilator.

2 optimal hemodynamic response to intravenous vasodilator.

3 eptide (CGRP) is a potent neuromodulator and vasodilator.

4 Thus, CCt is a bi-modal vasodilator.

5 ptide (CGRP) is a potent arterial and venous vasodilator.

6 ction, although CCt was a far more effective vasodilator.

7 ionine gamma-lyase (CSE), is a proangiogenic vasodilator.

8 n pulmonary hypertension that functions as a vasodilator.

9 iesterase type 5 (PDE5) inhibitor and potent vasodilator.

10 cal treatment and injection of intraarterial vasodilators.

11 r both at rest and in response to endogenous vasodilators.

12 permanent hypoxia to generate the metabolic vasodilators.

13 erity assessment without the need for potent vasodilators.

14 reater likelihood of stroke volume drop with vasodilators.

15 ion as 'amplifiers' of endothelium-dependent vasodilators.

16 Nineteen studies (14 vasodilator, 4 dobutamine, and 1 that used both) involve

17 asopressors and/or inotropes, 9% versus 16%; vasodilators, 6% versus 12%; and any of these interventi

18 te the response to the endothelium-dependent vasodilator acetylcholine.

19 ng (1) infusion of the endothelium-dependent vasodilators acetylcholine (ACh) and adenosine triphosph

20 The vasodilator actions of insulin contribute to glucose upt

21 ng member of the conserved Ena/VASP (Enabled/Vasodilator Activated Protein) family is regulated by mi

22 sed expression of the focal adhesion protein vasodilator-activated phospho-protein (VASP), although t

23 din E synthase-1) depends critically for its vasodilator activity on the level of glutathione in the

24 ium-dependent and nitric oxide (NO)-mediated vasodilator activity, given its contribution to shear st

25 e amplitude of the oscillations, whereas the vasodilator adenosine (ADO, 10(-4) M) reduced oscillatio

26 We hypothesized that the metabolic vasodilator adenosine facilitates and that inhibition of

27 ntracted arterioles to endothelium-dependent vasodilators adenosine 5'-diphosphate (ADP) and substanc

28 by a decrease in production of the pulmonary vasodilator adrenomedullin of almost 70% (P </= 0.05).

29 Sildenafil and nitroglycerin (NTG) are vasodilator agents that may affect skin flap survival.

30 Bradykinin (BK) is one of the most potent vasodilator agonists known and belongs to the kinin fami

31 ing (i) infusion of an endothelium-dependent vasodilator alone (Protocol 1: ACh or Protocol 2: low do

32 Nitric oxide (NO), a potent vasodilator and a regulator of many physiological proces

33 ed by vascular endothelial cells is a potent vasodilator and an antiinflammatory mediator.

34 ossessing a signalling profile indicative of vasodilator and anti-fibrotic properties.

35 active Intestinal Peptide (VIP), a pulmonary vasodilator and inhibitor of vascular smooth muscle prol

36 , suggests that intravascular ATP exerts its vasodilator and sympatholytic effects directly, and not

37 ular weight kininogen to generate the potent vasodilator and the pro-inflammatory peptide, bradykinin

38 tors (GPCRs) contribute to the regulation of vasodilator and vasoconstrictor responses, and their act

39 Though modulated by endothelial-derived vasodilators and constrictors, O2 sensing is intrinsic t

40 phosphate-antagonist an adjunct therapy with vasodilators and gpIIb/IIIa inhibitors was given and rep

41 n impaired endothelium-dependent response to vasodilators and hyperresponse to vasoconstrictors.

42 mplications for care of older adults because vasodilators and oral beta-blockers are drugs that are u

43 be improved via the local administration of vasodilators and other smooth muscle relaxants.

44 have also investigated the role of pulmonary vasodilators and phosphodiesterase inhibitors in selecte

45 egments, whose contraction can be altered by vasodilators and vasoconstrictors.

46 d lipoxygenase metabolites prostaglandin E2 (vasodilator) and 12-hydroxyeicosatetraenoicacid (chemoat

47 unctional hyperemia), topical application of vasodilators, and decreases in blood pressure (CBF autor

48 Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could

49 es with established benefit in HFrEF such as vasodilators are frequently prescribed for HFpEF.

50 needed to reinforce awareness that pulmonary vasodilators are unlikely to benefit group 2/3 pulmonary

51 ty to endothelium-dependent and -independent vasodilators as well as vascular compliance in the setti

52 metry (LTA), VerifyNow P2Y12 (VN-P2Y12), and vasodilator-associated stimulated phosphoprotein (VASP).

53 y, exogenously administered nitrite is not a vasodilator at physiological concentrations in the vascu

54 sly halting the NEP-dependent degradation of vasodilator atrial natriuretic peptide.

55 In conclusion, BPA and pulmonary vasodilators both improve 6MWD and hemodynamics in patie

56 surgery, we found that milrinone acted as a vasodilator but did not demonstrate an improvement in th

57 ognized recently as an endothelium-dependent vasodilator, but several lines of evidence indicate that

58 poxia via the emission of multiple metabolic vasodilators by parenchymal cells.

59 ered in pathological states, we injected the vasodilator calcitonin gene-related peptide (CGRP), whic

60 The potent vasodilator calcitonin gene-related peptide mediates neu

61 A stepwise algorithm incorporating both vasodilators can accurately identify an ischemic cause i

62 ies in BL women suggest that, while impaired vasodilator capacity is involved, heightened vasoconstri

63 The vasodilator capacity to pressure was significantly lower

64 /NAD(P)Hoxidase protein ratio is a marker of vasodilator capacity.

65 arbon dioxide gas mixture, which is a potent vasodilator causing an increase of CBF.

66 years; P<0.0001), were more unresponsive to vasodilator challenge (0/7 versus 140/1055 [13.2%]), had

67 t anterior descending artery (LAD) underwent vasodilator challenges with hypercapnia and adenosine.

68 was calculated during 1) adenosine infusion (vasodilator control), 2) hypoxia (FIO2 = 10%), 3) endoto

69 ry drugs, aggressive analgesia, and possibly vasodilators could abort the crisis and prevent or minim

70 at O2 -dependent inhibition of production of vasodilator cyclooxygenase products or O2 -dependent des

71 ors worsened left-to-right shunting, whereas vasodilators decreased shunting at the expense of worsen

72 This endothelial vasodilator dysfunction during early diabetes may contri

73 d/-) mice, age-related endothelium-dependent vasodilator dysfunction in Xpd(TTD) animals was increase

74 Coronary vasodilator dysfunction is a powerful, independent corre

75 ypoxic mice (P < 0.001), suggesting that the vasodilator effect of AICAR was selective for the uterin

76 rict fetal growth markedly augmented the UtA vasodilator effect of AMPK activation in opposition to P

77 Blocking adiponectin abolished the vasodilator effect of insulin in the presence of C57BL/6

78 w attenuated angiotensin (ANG)-(1-7)-induced vasodilator effect, endothelial nitric oxide synthase (e

79 , exerts positive inotropic, lusitropic, and vasodilator effects in vivo that are cAMP independent.

80 Vasodilator effects of acetylcholine, which acts via end

81 Enabled/Vasodilator (Ena/VASP) proteins promote actin filament a

82 othelin-1) and higher levels of the 2 potent vasodilator factors apelin and ADM (adrenomedullin) comp

83 pulmonary, but not systemic, effects of the vasodilators, fasudil and imatinib, in PAH rats.

84 vascular magnetic resonance (cine, T2* iron, vasodilator first pass myocardial perfusion, and late ga

85 mins (2C); more common use of inotropes and vasodilators for low cardiac output septic shock associa

86 (Vasodilator Free Measure of Fractional Flow Reserve [ADV

87 The instantaneous wave-free ratio (iFR) is a vasodilator-free pressure-only measure of the hemodynami

88 Inter-relations of aortic stiffness and vasodilator function with incident CVD remain incomplete

89 y prevented the detrimental effect of CRP on vasodilator function, whereas anti-CD32 antibody treatme

90 rtension and arterial stiffness by improving vasodilator function.

91 tracoronary therapies, such as thrombolysis, vasodilators, glycoprotein IIb/IIIa inhibitors, and anti

92 lure, early intervention with an intravenous vasodilator has been proposed as a therapeutic goal to r

93 for age, gender, and other factors, using a vasodilator (hazard ratio [HR], 1.72; 95% confidence int

94 is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to cardiovascular a

95 diet and treated with angiotensin II and the vasodilator hydralazine to prevent hypertension showed d

96 th the levels induced by the ACE-independent vasodilator hydralazine.

97 s, and the prodrug was shown to be an active vasodilator in rat isolated perfused kidneys (EC50 ~50 m

98 hypothesis that exogenous nitrite acts as a vasodilator in the cephalic vasculature of the intact, n

99 ugmentation in response to a pharmacological vasodilator in the presence of nonobstructive coronary a

100 imately 70% and both oral spironolactone and vasodilators in approximately 90%, euvolemia was reached

101 e misexpression of both vasoconstrictors and vasodilators in multiple pathways that converge to incre

102 hance the pulmonary vascular effects of i.v. vasodilators in Sugen5416/hypoxia/normoxia-exposed PAH r

103 timulates the expression of apelin, a potent vasodilator, in response to reduced blood arterial oxyge

104 Many vasodilators including angiotensin-converting enzyme inh

105 Vasodilator-induced elevation of intracellular cyclic AM

106 The vasodilator-induced second messenger cAMP can relax vasc

107 t vasoconstriction to PE was observed during vasodilator infusion alone and mild exercise, and this w

108 the catheterization, pre-procedural systemic vasodilator infusion, and hemodialysis were independentl

109 on in resting skeletal muscle during control vasodilator infusions (DeltaFVC: ACh: -31 +/- 3 and ATP:

110 ia, which was only resolved by intracoronary vasodilator injection.

111 onin gene-related peptide (CGRP) is a potent vasodilator involved in migraine pathophysiology.

112 Nitric oxide (NO) is a powerful vasodilator, involved in both physiological functions an

113 on and diminished effectiveness of CGRP as a vasodilator is multifaceted and may adversely affect spl

114 Pulmonary delivery of vasodilators is a promising alternative for the intraven

115 Use of vasodilators is associated with a 72% increase in the ha

116 gene-related peptide), one of the strongest vasodilators, is cardioprotective in hypertension by red

117 flow reserve with an endothelium-independent vasodilator like adenosine, but the optimal diagnostic t

118 Selective pulmonary vasodilators, like phosphodiesterase-5 inhibitors (PDE5i

119 ns in the ureter, clinically prescribed oral vasodilators may improve spontaneous stone passage rates

120 Although pulmonary arterial vasodilators may often be considered in this setting, th

121 e embryonic heart, and improved NO-dependent vasodilator mechanisms in the peripheral circulation.

122 jor categories of therapeutic agents include vasodilators, mesenchymal stem cells, antiinflammatory a

123 by high levels of carbon monoxide, a potent vasodilator molecule generated by charcoal combustion.

124 Counterintuitively, release of the vasodilator molecule nitric oxide attenuated endothelial

125 amounts of carbon monoxide (CO), a putative vasodilator molecule.

126 patients underwent SE (exercise, n = 1,288; vasodilator, n = 1,860; dobutamine, n = 262) based on ne

127 xus neurons and non-cholinergic secretomotor/vasodilator neurons in the submucosal plexus.

128 reathing (Amb) and a 6 min inhalation of the vasodilator nitric oxide (iNO; 40 ppm in 21% O(2) ), to

129 synthase (eNOS), which generates the potent vasodilator nitric oxide (NO), is decreased.

130 increasing the bioavailability of the potent vasodilator nitric oxide (NO).

131 SD95) and a reduced production of the potent vasodilator nitric oxide during glutamatergic synaptic a

132 ly higher perfusate levels of the endogenous vasodilator nitric oxide.

133 e the bioactivity of the endothelium-derived vasodilator NO by enhancing NO synthesis or by decreasin

134 associated with weight loss, increase in the vasodilator NO, and decrease in lipid oxidation.

135 vasodilator-responsive IPAH (VR-PAH) versus vasodilator-nonresponsive IPAH (VN-PAH).

136 um channel blockers and better survival than vasodilator-nonresponsive PAH (VN-PAH).

137 e results demonstrate that H2S is a powerful vasodilator of the placental vasculature and that expres

138 rectomy (inoperable CTEPH) include pulmonary vasodilators or balloon pulmonary angioplasty (BPA).

139 Intrathecal administration of vasodilators or fibrinolytics may have offered advantage

140 dent increase in forearm blood flow with all vasodilators (P<0.001), which was attenuated by fire sim

141 ciated with greater adherence to recommended vasodilators (P=0.04).

142 crobials sanguinarine and berberine, and the vasodilator papaverine.

143 ed that abnormalities in endothelial-derived vasodilator pathways are temporally associated with the

144 Several vasodilator pathways have been proposed and examined as

145 sodium-potassium ATPase pump, two potential vasodilator pathways within blood vessels, contributes t

146 fter inhibiting shear- or pressure-dependent vasodilator pathways, and in mice with hindlimb ischemia

147 nsatory response through endothelial-derived vasodilator pathways.

148 e (NO) and prostacyclin trigger well-defined vasodilator pathways; however, substantial vasorelaxatio

149 Production of adrenomedullin (ADM), a vasodilator peptide, increases in response to ischemia a

150 t astrocyte calcium-evoked production of the vasodilator PgE2 is critically dependent on brain levels

151 flow (CBF) increases via the release of the vasodilator PgE2 We demonstrate that hypercapnia (increa

152 tment with Nifedipine (Ca(2+) antagonist and vasodilator) prevented cocaine-induced CBF decreases and

153 Conversely, endothelial-derived vasodilators progressively increased over 18 months and

154 escue treatments including inhaled pulmonary vasodilators, prone positioning, or extracorporeal membr

155 olism, has shown nitric oxide (NO)-dependent vasodilator properties in experimental models.

156 Nitrite exhibits hypoxia-dependent vasodilator properties, selectively dilating capacitance

157 comitant positive inotropic, lusitropic, and vasodilator properties.

158 Vasodilator prostanoid contribution to endothelium-depen

159 ers, 95% CI: 34.5-61.2 meters with pulmonary vasodilators), PVR [-3.1 Wood Units (WU), 95% CI: -4.9 t

160 Obese patients have impaired vasodilator reactivity and increased endothelin 1 (ET-1)

161 hat its actions are independent of the known vasodilator receptors of the RAS, Mas, and angiotensin I

162 ith exercise, and depressed pulmonary artery vasodilator reserve.

163 A physically active lifestyle keeps both the vasodilator response and microvascular density high.

164 It is unknown whether diminished coronary vasodilator response correlates with abnormal exercise p

165 festyle keeps both microvascular density and vasodilator response high.

166 Thus, the attenuated skin vasodilator response in CHF patients is not attributable

167 ary lifestyle, obesity and ageing impair the vasodilator response of the muscle microvasculature to i

168 s becoming increasingly apparent that a high vasodilator response of the skeletal muscle microvascula

169 pulmonary arterial hypertension (PAH), acute vasodilator response testing (AVT) is considered importa

170 to assess pulmonary endothelial function by vasodilator response to acetylcholine (Ach) administered

171 particulate pollution is not associated with vasodilator response, but that particulate air pollution

172 As ATP released from RBC is known to exert a vasodilator response, these results suggest a role for p

173 besity and ageing lead to impairments in the vasodilator response, while a physically active lifestyl

174 Vasodilator responses after inhibition of NO synthase bl

175 llow-up studies, BaCl(2) alone inhibited the vasodilator responses to ATP on average 51 +/- 3% (n = 6

176 ded a brachial arterial catheter for forearm vasodilator responses to isoprenaline with plethysmograp

177 ld influence the cardiovascular and regional vasodilator responses to sympathoexcitatory manoeuvres f

178 ing IPAH and determine whether GVs differ in vasodilator-responsive IPAH (VR-PAH) versus vasodilator-

179 Although vasodilator-responsive PAH (VR-PAH) accounts for a minor

180 ine coronary flow reserve were calculated as vasodilator/resting coronary blood flow (CFR and AchFR,

181 Here, we report that papaverine, a vasodilator, shows inhibitory action against various str

182 Acidosis is a powerful vasodilator signal in the brain circulation.

183 of cardiovascular health, yet the underlying vasodilator signaling pathways are controversial and thu

184 Thus, mechanisms of integration of vasodilator signalling across elements of the microvascu

185 ontraction) and in relation to the spread of vasodilator signals up- and downstream throughout the ne

186 6), 12 weeks of treatment with the pulmonary vasodilator sildenafil or placebo led to a 24.6% increas

187 substance P and the endothelium-independent vasodilator sodium nitroprusside (SNP) were examined.

188 phosphate (ATP), the endothelium-independent vasodilator (sodium nitroprusside, SNP), or potassium ch

189 schemia testing at 34 centers underwent rest/vasodilator SonoVue-enhanced flash-replenishment MCE, st

190 On-treatment vasodilator stimulated phosphoprotein P2Y(12) platelet r

191 ted proteins including pVASP (phosphorylated vasodilator stimulated phosphoprotein), cortactin and vi

192 Enabled/Vasodilator-stimulated phosphoprotein (Ena/VASP) protein

193 We used Enabled/vasodilator-stimulated phosphoprotein (Ena/VASP)-deficie

194 The APC was not correlated with vasodilator-stimulated phosphoprotein (p = 0.16).

195 the induction of (protein kinase A) phospho-vasodilator-stimulated phosphoprotein (p-VASP) by isopro

196 r, AKAR4-NES, and induced phosphorylation of vasodilator-stimulated phosphoprotein (VASP) and CREB.

197 Vasodilator-stimulated phosphoprotein (VASP) and Ena-VAS

198 Vasodilator-stimulated phosphoprotein (VASP) can catalyz

199 (SH3), WW, GYF, and Drosophila enabled (Ena)/vasodilator-stimulated phosphoprotein (VASP) homology 1

200 Vasodilator-stimulated phosphoprotein (VASP) is active i

201 n this study, we sought to determine whether vasodilator-stimulated phosphoprotein (VASP) signaling i

202 Action of Enabled (Ena)/vasodilator-stimulated phosphoprotein (VASP), a family o

203 were induced by macrophage overexpression of vasodilator-stimulated phosphoprotein (VASP), a key down

204 partners alpha-actinin and p130Cas, but not vasodilator-stimulated phosphoprotein and cysteine-rich

205 ostanes, and thromboxane A(2), and increased vasodilator-stimulated phosphoprotein and nitric oxide.

206 care P2Y(12) platelet-reactivity test, and a vasodilator-stimulated phosphoprotein assay.

207 sured by light transmittance aggregometry or vasodilator-stimulated phosphoprotein assays, was numeri

208 associated with fascin along the length and vasodilator-stimulated phosphoprotein at the tip.

209 pendent exocytosis of the late endosome in a vasodilator-stimulated phosphoprotein envelope.

210 sphate receptor blockade was assessed by the vasodilator-stimulated phosphoprotein index.

211 d or prevented by postsynaptic expression of vasodilator-stimulated phosphoprotein phospho-mimetic or

212 al cyclic adenosine monophosphate (cAMP) and vasodilator-stimulated phosphoprotein phosphorylation (V

213 Inhibition of vasodilator-stimulated phosphoprotein phosphorylation an

214 d IPA was lower and P2Y12 reaction units and vasodilator-stimulated phosphoprotein phosphorylation an

215 d significant positive correlations with the vasodilator-stimulated phosphoprotein phosphorylation as

216 5 and 20 mumol/l and arachidonic acid), and vasodilator-stimulated phosphoprotein phosphorylation as

217 (P2Y12 assay) and platelet reactivity index (vasodilator-stimulated phosphoprotein phosphorylation as

218 PD was assessed by using VerifyNow P2Y12 and vasodilator-stimulated phosphoprotein phosphorylation as

219 to dense granules, as confirmed by increased vasodilator-stimulated phosphoprotein phosphorylation in

220 and PKA, as determined by Rap1 activity and vasodilator-stimulated phosphoprotein phosphorylation, r

221 h using light transmission aggregometry and vasodilator-stimulated phosphoprotein phosphorylation.

222 ith different agonists as well as changes in vasodilator-stimulated phosphoprotein platelet reactivit

223 esidual platelet aggregation, p = 0.005) and vasodilator-stimulated phosphoprotein platelet reactivit

224 ogaster Enabled (Ena) is a member of the Ena/vasodilator-stimulated phosphoprotein protein family, wh

225 Ras homolog gene family member A (RhoA) and vasodilator-stimulated phosphoprotein was increased in r

226 aramagnetic resonance and phosphorylation of vasodilator-stimulated phosphoprotein were determined.

227 eletal regulatory proteins of the Mena/VASP (vasodilator-stimulated phosphoprotein) family.

228 1) binding domains of Lpd and the host VASP (vasodilator-stimulated phosphoprotein) recruited to the

229 (PKG)-mediated phosphorylation of the VASP (vasodilator-stimulated phosphoprotein) Ser239 residue wh

230 racellular signal-related kinase), and VASP (vasodilator-stimulated phosphoprotein).

231 as an established protein substrate of PKG (vasodilator-stimulated phosphoprotein).

232 ated with increased mRNA expression of VASP (vasodilator-stimulated phosphoprotein).

233 ion occurs because of associations involving vasodilator-stimulated phosphoprotein, focal adhesion ki

234 ion occurs because of associations involving vasodilator-stimulated phosphoprotein, focal adhesion ki

235 in in response to S-nitrosylation, including vasodilator-stimulated phosphoprotein, focal adhesion ki

236 Pharmacodynamic assessments measured by vasodilator-stimulated phosphoprotein, light transmittan

237 different assays, including VerifyNow P2Y12, vasodilator-stimulated phosphoprotein, light transmittan

238 let Nox2, Rac1, p47(phox), protein kinase C, vasodilator-stimulated phosphoprotein, nitric oxide, and

239 y Artery Bypass Graft (APTITUDE-CABG) study, vasodilator-stimulated phosphoprotein-platelet reactivit

240 activation of cofilin 1 and inactivation of vasodilator-stimulated phosphoprotein.

241 al nitric oxide synthase, and phosphorylated vasodilator-stimulated phosphoprotein.

242 ng mislocalization of the TJ binding protein vasodilator-stimulated phosphoprotein.

243 y VerifyNow and platelet reactivity index by vasodilator-stimulated phosphoprotein.

244 arinic-induced phosphorylation of Ser-239 in vasodilator-stimulated phosphoprotein.

245 tions between the C-terminal EVH1 (Ena/VASP [vasodilator-stimulated phosphoprotein] homology domain 1

246 n=47) underwent CMR for assessment of DE and vasodilator stress ammonia positron emission tomography

247 Vasodilator stress and rest myocardial perfusion CMR and

248 CMR) included gadobutrol-enhanced first-pass vasodilator stress and rest perfusion followed by LGE im

249 Vasodilator stress cardiac magnetic resonance (CMR) can

250 Vasodilator stress cardiac MRI was performed in 118 wome

251 dial perfusion and tissue oxygenation during vasodilator stress in patients with overt hypertrophic c

252 Myocardial perfusion under vasodilator stress is impaired in patients with HCM.

253 Participants with RA underwent rest and vasodilator stress N-13 ammonia positron emission tomogr

254 he aim was to assess the prognostic value of vasodilator stress perfusion CMR in patients with HFrEF.

255 ion fraction <40% prospectively referred for vasodilator stress perfusion CMR were followed for the o

256 cardiovascular magnetic resonance including vasodilator stress perfusion mapping.

257 using (99m)Tc-tetrofosmin at rest and after vasodilator stress were performed using a dedicated cadm

258 g with (99m)Tc-sestamibi at rest and at peak vasodilator stress, followed by standard gated MPI.

259 CT evaluation of myocardial perfusion during vasodilator stress, thereby providing information about

260 erfusion and oxygenation are impaired during vasodilator stress.

261 Endothelium-dependent vasodilators, such as acetylcholine, increase intracellu

262 We evaluated the contribution of systemic vasodilators (SVD) to the management of DAA after OLT.

263 mportant building block for the synthesis of vasodilator taprostene.

264 Despite inpatient diuretics and vasodilators targeting decongestion, persistent congesti

265 tations were less likely to respond to acute vasodilator testing (3% [10 of 380] vs 16% [147 of 907];

266 PH (r = -0.89), and acute reductions during vasodilator testing (r = -0.89, p </= 0.01 for all).

267 ry pressure and SCmin at baseline and during vasodilator testing (r=-0.81 and -0.85, respectively; P<

268 o cardiac output both at baseline and during vasodilator testing (r=-0.88 and -0.87, respectively; P<

269 ic PH (n = 22); and 3) changes in PVR during vasodilator testing in chronic PH (n = 10).

270 monary hypertension (PH) and the response to vasodilator testing require invasive right heart cathete

271 ute changes in pulmonary hemodynamics during vasodilator testing.

272 Active nerve cells release vasodilators that increase their energy supply by dilati

273 The probes are reversibly caged vasodilators that induce responses detectable by hemodyn

274 al forces and, in response, releases various vasodilators that relax smooth muscle cells in a process

275 re information, more changes in diuretic and vasodilator therapies were made in the treatment group.

276 terectomy, balloon pulmonary angioplasty, or vasodilator therapies.

277 without pulmonary vasodilators to pulmonary vasodilator therapy alone in patients with inoperable CT

278 ility is modifiable with selective pulmonary vasodilator therapy and may represent an important targe

279 approach in the presence of standard of care vasodilator therapy is mediated by a reduction in pulmon

280 dence-based treatment options, and pulmonary vasodilator therapy may lead to worsening symptoms.

281 correlated with the initiation of pulmonary vasodilator therapy post-PEA.

282 Finally, we show that standard oral vasodilator therapy reduced contraction amplitude by onl

283 Treatment of hypertension with vasodilator therapy results in a lowering of the total L

284 n, peritoneal dialysis, oral sodium binders, vasodilator therapy, renal sympathetic denervation and a

285 t 3 to 5 years and did not require pulmonary vasodilator therapy.

286 s facilitate direct delivery of short acting vasodilator therapy.

287 vasopressors, renal replacement therapy, or vasodilator therapy.

288 Because NO is a potent vasodilator, these neurons could translate neuronal sign

289 duced ejection fraction receiving aggressive vasodilator titration.

290 ty outcomes of BPA with or without pulmonary vasodilators to pulmonary vasodilator therapy alone in p

291 isease or lung disease, the use of pulmonary vasodilator treatment has not been proven to be safe and

292 e as an alternative to current pharmacologic vasodilators used for cardiac stress testing.

293 Short-term infusions of single vasodilators, usually given in a fixed dose, have not im

294 ifference in efficacy, the EC50 of CGRP as a vasodilator was approximately 6-fold greater in Old vers

295 Pre-procedural use of pulmonary vasodilators was associated with reduced risk of composi

296 ,5'-cyclic guanosine monophosphate, a potent vasodilator, was greater in skin samples from null mice

297 ns of endothelial-dependent and -independent vasodilators were measured.

298 mited by the simultaneous release of several vasodilators with an effect size sequence of nitric oxid

299 Epoxyeicosatrienoic acids are vasodilators with anti-inflammatory properties that oppo

300 lizes the response of mesenteric arteries to vasodilators, with beneficial effects on portal hyperten